Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation

C. Hurny, J. Bernhard, A. Coates, M. Castiglione, H. F. Peterson, R. D. Gelber, C. M. Rudenstam, A. Goldhirsch, H. J. Senn, B. Gusterson, R. Bettelheim, R. Reed, M. Helg, U. Hurlimann, A. Hangartner, K. Price, M. Zelen, M. Isley, R. Hinkle

Research output: Contribution to journalArticle

Abstract

Background: Variability in timing of baseline quality of life (QL) assessments in two ongoing International Breast Cancer Study Group (IBCSG) randomized clinical trials occurred as a result of allowing some flexibility in the timing. This retrospective report describes the QL timing in relation to surgery and start of adjuvant therapy and its effect on QL self-estimation. Patients and methods: Self-administered measures of baseline QL were obtained on day 1 of adjuvant therapy or as close to that date as possible from 1389 pre- and postmenopausal women with operable breast cancer. Results: Fifty-four percent of QL assessments were done on day 1 of adjuvant therapy, 18% before day 1 and 28% after. An ANOVA, controlling for surgery, institution and language, showed that: for patients receiving endocrine therapy alone, QL improved as time from surgery increased, but start of adjuvant treatment had no effect, while for chemotherapy patients, appetite, physical well-being and, in premenopausal patients, coping were worse 1 to 5 days after the start of treatment. Chemotherapy had little effect on mood and emotional well-being. Conclusions: Timing of QL assessment in relation to diagnosis affects global adjustment measures; timing in relation to chemotherapy affects measures sensitive to toxicity. Timing is an important consideration in study conduct and data analysis.

Original languageEnglish
Pages (from-to)65-74
Number of pages10
JournalAnnals of Oncology
Volume5
Issue number1
Publication statusPublished - 1994

Fingerprint

Chemotherapy
Quality of Life
Breast Cancer
Surgery
Baseline
Timing
Breast Neoplasms
Therapy
Analysis of variance (ANOVA)
Toxicity
Drug Therapy
Therapeutics
Social Adjustment
Randomized Clinical Trial
Mood
Appetite
Quality of life
Breast cancer
Date
Percent

Keywords

  • adjuvant treatment
  • breast cancer
  • effect of timing
  • feasibility
  • international clinical trial
  • quality of life assessment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Cite this

Hurny, C., Bernhard, J., Coates, A., Castiglione, M., Peterson, H. F., Gelber, R. D., ... Hinkle, R. (1994). Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation. Annals of Oncology, 5(1), 65-74.

Timing of baseline quality of life assessment in an international adjuvant breast cancer trial : Its effect on patient self-estimation. / Hurny, C.; Bernhard, J.; Coates, A.; Castiglione, M.; Peterson, H. F.; Gelber, R. D.; Rudenstam, C. M.; Goldhirsch, A.; Senn, H. J.; Gusterson, B.; Bettelheim, R.; Reed, R.; Helg, M.; Hurlimann, U.; Hangartner, A.; Price, K.; Zelen, M.; Isley, M.; Hinkle, R.

In: Annals of Oncology, Vol. 5, No. 1, 1994, p. 65-74.

Research output: Contribution to journalArticle

Hurny, C, Bernhard, J, Coates, A, Castiglione, M, Peterson, HF, Gelber, RD, Rudenstam, CM, Goldhirsch, A, Senn, HJ, Gusterson, B, Bettelheim, R, Reed, R, Helg, M, Hurlimann, U, Hangartner, A, Price, K, Zelen, M, Isley, M & Hinkle, R 1994, 'Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation', Annals of Oncology, vol. 5, no. 1, pp. 65-74.
Hurny, C. ; Bernhard, J. ; Coates, A. ; Castiglione, M. ; Peterson, H. F. ; Gelber, R. D. ; Rudenstam, C. M. ; Goldhirsch, A. ; Senn, H. J. ; Gusterson, B. ; Bettelheim, R. ; Reed, R. ; Helg, M. ; Hurlimann, U. ; Hangartner, A. ; Price, K. ; Zelen, M. ; Isley, M. ; Hinkle, R. / Timing of baseline quality of life assessment in an international adjuvant breast cancer trial : Its effect on patient self-estimation. In: Annals of Oncology. 1994 ; Vol. 5, No. 1. pp. 65-74.
@article{6564befba3e34254b93df97348dfb306,
title = "Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation",
abstract = "Background: Variability in timing of baseline quality of life (QL) assessments in two ongoing International Breast Cancer Study Group (IBCSG) randomized clinical trials occurred as a result of allowing some flexibility in the timing. This retrospective report describes the QL timing in relation to surgery and start of adjuvant therapy and its effect on QL self-estimation. Patients and methods: Self-administered measures of baseline QL were obtained on day 1 of adjuvant therapy or as close to that date as possible from 1389 pre- and postmenopausal women with operable breast cancer. Results: Fifty-four percent of QL assessments were done on day 1 of adjuvant therapy, 18{\%} before day 1 and 28{\%} after. An ANOVA, controlling for surgery, institution and language, showed that: for patients receiving endocrine therapy alone, QL improved as time from surgery increased, but start of adjuvant treatment had no effect, while for chemotherapy patients, appetite, physical well-being and, in premenopausal patients, coping were worse 1 to 5 days after the start of treatment. Chemotherapy had little effect on mood and emotional well-being. Conclusions: Timing of QL assessment in relation to diagnosis affects global adjustment measures; timing in relation to chemotherapy affects measures sensitive to toxicity. Timing is an important consideration in study conduct and data analysis.",
keywords = "adjuvant treatment, breast cancer, effect of timing, feasibility, international clinical trial, quality of life assessment",
author = "C. Hurny and J. Bernhard and A. Coates and M. Castiglione and Peterson, {H. F.} and Gelber, {R. D.} and Rudenstam, {C. M.} and A. Goldhirsch and Senn, {H. J.} and B. Gusterson and R. Bettelheim and R. Reed and M. Helg and U. Hurlimann and A. Hangartner and K. Price and M. Zelen and M. Isley and R. Hinkle",
year = "1994",
language = "English",
volume = "5",
pages = "65--74",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Timing of baseline quality of life assessment in an international adjuvant breast cancer trial

T2 - Its effect on patient self-estimation

AU - Hurny, C.

AU - Bernhard, J.

AU - Coates, A.

AU - Castiglione, M.

AU - Peterson, H. F.

AU - Gelber, R. D.

AU - Rudenstam, C. M.

AU - Goldhirsch, A.

AU - Senn, H. J.

AU - Gusterson, B.

AU - Bettelheim, R.

AU - Reed, R.

AU - Helg, M.

AU - Hurlimann, U.

AU - Hangartner, A.

AU - Price, K.

AU - Zelen, M.

AU - Isley, M.

AU - Hinkle, R.

PY - 1994

Y1 - 1994

N2 - Background: Variability in timing of baseline quality of life (QL) assessments in two ongoing International Breast Cancer Study Group (IBCSG) randomized clinical trials occurred as a result of allowing some flexibility in the timing. This retrospective report describes the QL timing in relation to surgery and start of adjuvant therapy and its effect on QL self-estimation. Patients and methods: Self-administered measures of baseline QL were obtained on day 1 of adjuvant therapy or as close to that date as possible from 1389 pre- and postmenopausal women with operable breast cancer. Results: Fifty-four percent of QL assessments were done on day 1 of adjuvant therapy, 18% before day 1 and 28% after. An ANOVA, controlling for surgery, institution and language, showed that: for patients receiving endocrine therapy alone, QL improved as time from surgery increased, but start of adjuvant treatment had no effect, while for chemotherapy patients, appetite, physical well-being and, in premenopausal patients, coping were worse 1 to 5 days after the start of treatment. Chemotherapy had little effect on mood and emotional well-being. Conclusions: Timing of QL assessment in relation to diagnosis affects global adjustment measures; timing in relation to chemotherapy affects measures sensitive to toxicity. Timing is an important consideration in study conduct and data analysis.

AB - Background: Variability in timing of baseline quality of life (QL) assessments in two ongoing International Breast Cancer Study Group (IBCSG) randomized clinical trials occurred as a result of allowing some flexibility in the timing. This retrospective report describes the QL timing in relation to surgery and start of adjuvant therapy and its effect on QL self-estimation. Patients and methods: Self-administered measures of baseline QL were obtained on day 1 of adjuvant therapy or as close to that date as possible from 1389 pre- and postmenopausal women with operable breast cancer. Results: Fifty-four percent of QL assessments were done on day 1 of adjuvant therapy, 18% before day 1 and 28% after. An ANOVA, controlling for surgery, institution and language, showed that: for patients receiving endocrine therapy alone, QL improved as time from surgery increased, but start of adjuvant treatment had no effect, while for chemotherapy patients, appetite, physical well-being and, in premenopausal patients, coping were worse 1 to 5 days after the start of treatment. Chemotherapy had little effect on mood and emotional well-being. Conclusions: Timing of QL assessment in relation to diagnosis affects global adjustment measures; timing in relation to chemotherapy affects measures sensitive to toxicity. Timing is an important consideration in study conduct and data analysis.

KW - adjuvant treatment

KW - breast cancer

KW - effect of timing

KW - feasibility

KW - international clinical trial

KW - quality of life assessment

UR - http://www.scopus.com/inward/record.url?scp=0028057110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028057110&partnerID=8YFLogxK

M3 - Article

C2 - 8172795

AN - SCOPUS:0028057110

VL - 5

SP - 65

EP - 74

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -